
|Videos|August 26, 2021
Role of Second Generation FLT3 Inhibitors in AML
Expert examines the status of second-generation FLT3 inhibitors in newly diagnosed AML patients and the challenge with comparing clinical trial efficacy endpoints.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Should Know About Novo Nordisk-Eli Lilly GLP-1 Ad Suit
2
FDA Clears First Continuous Glucose-Ketone Monitor
3
FDA Approves Dolutegravirfor HIV Treatment in Newborns
4
Overlooked Coronavirus Protein May Drive Cytokine Storm, Cardiac Injury in Severe COVID-19
5


































































































